EBRO 2017

PORTEC-2 results

VBT EBRT

p value

Vaginal recurrence 1.8% 1.6% 0.74

Pelvic recurrence

5.1% 2.1% 0.17

Acute GI toxicity

12.6% 53.8%

VBT is adjuvant treatment of choice for patients with “high-intermediate risk” endometrial Ca